Physician profile
Benjamin Carcamo
NPI 1437362092
$5,084.25
in general payments reported to CMS, 2019-2025
24 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $96.67 · 2021: $237 · 2022: $1,217 · 2023: $975 · 2024: $899 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,958.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $874.64 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $776.08 | 2021-2025 | |
| Fennec Pharmaceuticals, INC. | $385.75 | 2023-2024 | Pedmark |
| Syndax Pharmaceuticals, INC. | $352.45 | 2025 | Revuforj |
| Alexion Pharmaceuticals, INC. | $283.41 | 2019-2023 | Koselugo |
| Agios Pharmaceuticals, INC. | $283.27 | 2022-2025 | Pyrukynd |
| Novo Nordisk INC | $237.29 | 2019-2024 | |
| Genentech USA, INC. | $173.53 | 2019 | |
| Uswm, LLC | $157.24 | 2024-2025 | Iwilfin |
| Horizon Therapeutics Plc | $155.62 | 2019-2022 | |
| Genentech, INC. | $147.88 | 2024 | Hemlibra |
| Octapharma USA, INC. | $144.85 | 2019-2022 | |
| Adaptive Biotechnologies Corporation | $127.87 | 2023 | Clonoseq |
| Shire North American Group INC | $127.46 | 2019 | |
| Amgen INC. | $125.00 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hema Biologics, LLC | $125.00 | 2025 | Sevenfact |
| Genzyme Corporation | $120.52 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.03 | 2022-2024 | Elaprase, Advate, Vpriv |
| Novartis Pharmaceuticals Corporation | $97.41 | 2022 | |
| United Therapeutics Corporation | $96.67 | 2020 | |
| Pharming Healthcare, INC. | $76.63 | 2023 | Joenja |
| Springworks Therapeutics, INC. | $59.06 | 2025 | Gomekli |
| Medtronic, INC. | $35.16 | 2023 | Stealthstation S8 Platform |
| Pfizer INC. | $13.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Carcamo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.